Potential to Treat More Stroke Patients
Our investigational drug product candidate, DM199 aims to preserve valuable brain tissue during the hours to weeks after an acute ischemic stroke (AIS). DM199 is intended to promote collateral circulation in the ischemic penumbra following a stroke and is being clinically studied with treatment initiated up to 24 hours after the onset of stroke symptoms. This is a treatment window five times longer than any existing therapy. DM199, as a protein replacement therapy, may also be a safer alternative for patients who are excluded from other treatment options because of clot location, delayed arrival at the emergency department or other safety considerations.